In vivo behavior of copper-64-labeled methanephosphonate tetraaza macrocyclic ligands.
Copper-64 ( T(1/2)=12.7 h; beta(+): 0.653 MeV, 17.4%; beta(-): 0.578 MeV, 39%) is produced in a biomedical cyclotron and has applications in both imaging and therapy. Macrocyclic chelators are widely used as bifunctional chelators to bind copper radionuclides to antibodies and peptides owing to their relatively high kinetic stability. In this paper, we evaluated three tetraaza macrocyclic ligands with two, three, and four pendant methanephosphonate functional groups. DO2P [1,4,7,10-tetraazacyclododecane-1,7-di(methanephosphonic acid)], DO3P [1,4,7,10-tetraazacyclododecane-1,4,7-tri(methanephosphonic acid)], and DOTP [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(methanephosphonic acid)] were all radiolabeled with (64)Cu in high radiochemical yields. Copper-64-labeled DO2P and DOTP were highly stable in rat serum out to 24 h, while (64)Cu-DO3P remained 73% intact, with the remainder possibly forming a (64)Cu(.)2DO3P dimer by 24 h. The biodistribution experiments were performed in normal Sprague-Dawley rats. Of the three complexes, (64)Cu-DO2P demonstrated the most optimal clearance through the blood and liver. Copper-64-DO3P and (64)Cu-DOTP exhibited higher liver uptake and longer retention of liver activity, possibly because of the large negative charge of the complexes under physiological conditions. All three (64)Cu-labeled complexes showed high accumulation in bone, likely due to the binding of the methanephosphonate groups to hydroxyapatite. These results suggest that this series of methanephosphonate macrocyclic ligands may be useful as potential bone-imaging agents. The thermodynamic stability constants of the Cu(II) complexes with these three ligands were determined, and were found to be significantly higher than those of their acetate analogues. The Cu(II)-DO2P complex exhibited the highest stability constant among divalent transition metal ion DO2P complexes. Metabolism studies of (64)Cu-DO2P in rat liver suggest that the DO2P ligand may be used as a bifunctional chelator for copper radionuclides in radiodiagnostic or radiotherapeutic studies.
Sun
Xiankai
X
The Edward Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO 63110, USA.
Wuest
Melinda
M
Kovacs
Zoltan
Z
Sherry
A Dean
AD
Motekaitis
Ramunas
R
Wang
Zheng
Z
Martell
Arthur E
AE
Welch
Michael J
MJ
Anderson
Carolyn J
CJ
D000818:Animals; D001952:Bridged-Ring Compounds / Q000737:chemistry* / Q000493:pharmacokinetics*; D002614:Chelating Agents; D003301:Copper Radioisotopes; D004355:Drug Stability; D005260:Female; D007553:Isotope Labeling; D008024:Ligands; D009942:Organometallic Compounds / Q000737:chemistry / Q000493:pharmacokinetics; D009943:Organophosphorus Compounds / Q000737:chemistry* / Q000493:pharmacokinetics*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013816:Thermodynamics; D014018:Tissue Distribution
D001952:Bridged-Ring Compounds; D002614:Chelating Agents; D003301:Copper Radioisotopes; D008024:Ligands; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D019275:Radiopharmaceuticals